HK1091488A1 - Pyrimidine derivatives - Google Patents
Pyrimidine derivativesInfo
- Publication number
- HK1091488A1 HK1091488A1 HK06112084.6A HK06112084A HK1091488A1 HK 1091488 A1 HK1091488 A1 HK 1091488A1 HK 06112084 A HK06112084 A HK 06112084A HK 1091488 A1 HK1091488 A1 HK 1091488A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrimidine derivatives
- pyrimidine
- derivatives
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45853003P | 2003-03-31 | 2003-03-31 | |
US49591103P | 2003-08-19 | 2003-08-19 | |
US51018603P | 2003-10-09 | 2003-10-09 | |
US53036003P | 2003-12-16 | 2003-12-16 | |
PCT/JP2004/004624 WO2004087669A1 (en) | 2003-03-31 | 2004-03-31 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1091488A1 true HK1091488A1 (en) | 2007-01-19 |
Family
ID=32854505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06112084.6A HK1091488A1 (en) | 2003-03-31 | 2006-11-02 | Pyrimidine derivatives |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050197350A1 (xx) |
EP (1) | EP1464335A3 (xx) |
JP (1) | JP2004300156A (xx) |
KR (1) | KR20050118704A (xx) |
AU (1) | AU2004226049A1 (xx) |
BR (1) | BRPI0408910A (xx) |
CA (1) | CA2518913A1 (xx) |
HK (1) | HK1091488A1 (xx) |
HR (1) | HRP20050780A2 (xx) |
MX (1) | MXPA05010475A (xx) |
NO (1) | NO20054999L (xx) |
TW (1) | TW200508202A (xx) |
WO (1) | WO2004087669A1 (xx) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7378409B2 (en) * | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
JP2007517868A (ja) * | 2004-01-07 | 2007-07-05 | アストラゼネカ アクチボラグ | 治療薬i |
WO2005075426A1 (en) * | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
US7230002B2 (en) | 2004-02-03 | 2007-06-12 | Glenmark Pharmaceuticals Ltd. | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof |
CN1976905A (zh) * | 2004-03-30 | 2007-06-06 | 大正制药株式会社 | 嘧啶衍生物以及与其应用有关的治疗方法 |
ES2350113T3 (es) | 2004-04-14 | 2011-01-18 | Amgen Inc. | Arilsulfonas y usos relacionados con las mismas. |
WO2006011035A1 (en) * | 2004-07-23 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them |
AP2007003973A0 (en) | 2004-10-12 | 2007-07-30 | Glenmark Pharmaceuticals Sa | Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation |
WO2006068594A1 (en) * | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY |
US8193206B2 (en) * | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
CA2612227C (en) * | 2005-06-14 | 2014-04-22 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
EP1893246A4 (en) * | 2005-06-23 | 2009-05-06 | Univ Emory | STEREOSELECTIVE SYNTHESIS OF AMINO ACID ANALOGUE FOR TUMOR IMAGING |
CA2612186A1 (en) | 2005-06-23 | 2007-01-04 | Emory University | Imaging agents |
JP2007091649A (ja) * | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
FR2902100A1 (fr) * | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
US7994317B2 (en) | 2006-11-03 | 2011-08-09 | GlaxoSmithKline, LLC | sEH inhibitors and their use |
CA2672494A1 (en) | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
AU2008254960B2 (en) | 2007-05-17 | 2014-11-27 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
WO2009011336A1 (ja) * | 2007-07-18 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | キノリン化合物 |
WO2009049165A1 (en) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
PL2214487T3 (pl) | 2007-10-11 | 2014-04-30 | Glaxosmithkline Llc | NOWE INHIBITORY sEH I ICH ZASTOSOWANIE |
US8246752B2 (en) | 2008-01-25 | 2012-08-21 | Clear Catheter Systems, Inc. | Methods and devices to clear obstructions from medical tubes |
EP2240021A4 (en) * | 2008-01-30 | 2011-08-17 | Glaxosmithkline Llc | NEW SEH-HEMMER AND ITS USE |
WO2009097476A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
US20100311775A1 (en) * | 2008-01-30 | 2010-12-09 | Smithkline Beecham Corporation | Novel sEH Inhibitors and Their Use |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
MX2011003500A (es) * | 2008-10-02 | 2011-05-02 | Taisho Pharma Co Ltd | Derivado de 7-piperidinoalquil-3,4-dihidroquinolona. |
WO2012061926A1 (en) * | 2010-11-08 | 2012-05-18 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
WO2014056620A1 (en) * | 2012-10-11 | 2014-04-17 | Grünenthal GmbH | Treatment and/or prophylaxis of tspo mediated diseases and/or disorders |
JP2021508336A (ja) * | 2017-12-13 | 2021-03-04 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
EP3782986A4 (en) * | 2018-03-29 | 2021-11-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
EP3801522A4 (en) | 2018-06-05 | 2022-06-01 | Praxis Biotech LLC | INTEGRATED STRESS RESPONSE PATHWAY INHIBITORS |
CN113412258A (zh) | 2019-01-18 | 2021-09-17 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
US20200270232A1 (en) * | 2019-02-25 | 2020-08-27 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
EP3982965A4 (en) | 2019-06-12 | 2023-01-25 | Praxis Biotech LLC | INTEGRATED STRESS RESPONSE PATHWAY MODULATORS |
BR112022000429A2 (pt) | 2019-07-11 | 2022-03-29 | Praxis Prec Medicines Inc | Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos |
US10702525B1 (en) * | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
DE4417163A1 (de) * | 1994-05-17 | 1995-11-23 | Hoechst Schering Agrevo Gmbh | Heterocyclylamino- und Heterocyclyloxy-cycloalkyl-Derivate, ihre Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
US7101878B1 (en) * | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
CZ2001523A3 (cs) * | 1998-08-20 | 2002-05-15 | Agouron Pharmaceuticals, Inc. | Nepeptidová GnRH činidla, způsob jejich přípravy a meziprodukty pro jejich výrobu |
CA2407149C (en) * | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
JP4329291B2 (ja) * | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 含窒素五員環化合物 |
JP4329290B2 (ja) * | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 脂肪族含窒素五員環化合物 |
EP1323710B1 (en) * | 2000-10-06 | 2008-09-10 | Mitsubishi Tanabe Pharma Corporation | Nitrogenous five-membered ring compounds |
EP1359915A4 (en) * | 2001-01-26 | 2004-07-21 | Smithkline Beecham | UROTENSIN-II RECEPTOR ANTAGONISTS |
IL158941A0 (en) * | 2001-05-22 | 2004-05-12 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
JP2005523237A (ja) * | 2001-10-01 | 2005-08-04 | 大正製薬株式会社 | Mch受容体アンタゴニスト |
CN100402521C (zh) * | 2001-10-22 | 2008-07-16 | 田边制药株式会社 | 4-咪唑啉-2-酮化合物 |
US7012077B2 (en) * | 2001-12-20 | 2006-03-14 | Hoffmann-La Roche Inc. | Substituted cyclohexane derivatives |
WO2003070244A1 (en) * | 2002-02-22 | 2003-08-28 | Abbott Laboratories | Antagonist of melanin concentrating hormone and their uses |
SE0202134D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
-
2004
- 2004-03-30 US US10/812,075 patent/US20050197350A1/en not_active Abandoned
- 2004-03-30 EP EP04007651A patent/EP1464335A3/en not_active Withdrawn
- 2004-03-31 TW TW093108879A patent/TW200508202A/zh unknown
- 2004-03-31 KR KR1020057018494A patent/KR20050118704A/ko not_active Application Discontinuation
- 2004-03-31 BR BRPI0408910-3A patent/BRPI0408910A/pt not_active IP Right Cessation
- 2004-03-31 JP JP2004107965A patent/JP2004300156A/ja active Pending
- 2004-03-31 WO PCT/JP2004/004624 patent/WO2004087669A1/en active Application Filing
- 2004-03-31 AU AU2004226049A patent/AU2004226049A1/en not_active Abandoned
- 2004-03-31 MX MXPA05010475A patent/MXPA05010475A/es not_active Application Discontinuation
- 2004-03-31 CA CA002518913A patent/CA2518913A1/en not_active Abandoned
-
2005
- 2005-09-06 HR HR20050780A patent/HRP20050780A2/xx not_active Application Discontinuation
- 2005-10-27 NO NO20054999A patent/NO20054999L/no not_active Application Discontinuation
-
2006
- 2006-11-02 HK HK06112084.6A patent/HK1091488A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HRP20050780A2 (en) | 2009-02-28 |
EP1464335A2 (en) | 2004-10-06 |
CA2518913A1 (en) | 2004-10-14 |
BRPI0408910A (pt) | 2006-03-21 |
EP1464335A3 (en) | 2007-05-09 |
AU2004226049A1 (en) | 2004-10-14 |
KR20050118704A (ko) | 2005-12-19 |
MXPA05010475A (es) | 2006-05-25 |
NO20054999L (no) | 2005-11-07 |
JP2004300156A (ja) | 2004-10-28 |
WO2004087669A1 (en) | 2004-10-14 |
US20050197350A1 (en) | 2005-09-08 |
TW200508202A (en) | 2005-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1091488A1 (en) | Pyrimidine derivatives | |
SI1487805T1 (sl) | Pirimidinski derivati | |
IL181433A0 (en) | Pyrimidine derivatives | |
HK1088602A1 (en) | 2-pyridinecarboxamide derivatives | |
HK1088326A1 (en) | Piperidine-benzenesulfonamide derivatives | |
IL181386A0 (en) | Pyrimidine derivatives | |
HK1089443A1 (en) | Imidazol-4-yl-ethynyl-pyridine derivatives | |
GB0317665D0 (en) | Qinazoline derivatives | |
GB0322409D0 (en) | Quinazoline derivatives | |
SI1682493T1 (sl) | Amidoacetonitrilni derivati | |
IL179914A0 (en) | Pyrimidine derivatives | |
GB0321648D0 (en) | Quinazoline derivatives | |
GB0415364D0 (en) | Pyrimidine derivatives | |
IL175189A0 (en) | N-thiazol-2-yl-benzamide derivatives | |
GB0415367D0 (en) | Pyrimidine derivatives | |
PL1706373T3 (pl) | Pochodne amidoacetonitrylu | |
GB0319793D0 (en) | Pyridinylmorpholine derivatives | |
GB0321621D0 (en) | Quinazoline derivatives | |
GB0321620D0 (en) | Quinazoline derivatives | |
GB0227443D0 (en) | Pyrimidine derivatives | |
GB0219305D0 (en) | Pyrimidine derivatives | |
GB0219304D0 (en) | Pyrimidine derivatives | |
TWI341309B (en) | Heteroarylcarbamoylbenzene derivatives | |
GB0319148D0 (en) | Azaquinazoline derivatives | |
AU2003280822A8 (en) | Beauveriolide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130331 |